Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
-
Could CAR-T cells tame multiple sclerosis? early trial launches
Disease control Recruiting nowThis early study tests a single dose of GC012F CAR-T cell injection in 9 people with multiple sclerosis. The main goal is to check safety and tolerability, not yet to see if it works. Researchers will monitor side effects for up to 15 years and measure how the cells behave in blo…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
CAR-T cells take on stubborn muscle disease in first human test
Disease control Recruiting nowThis early-phase trial tests a new treatment called GC012F, which uses a patient's own immune cells (CAR-T cells) to target and attack the cause of idiopathic inflammatory myopathy, a group of rare muscle diseases. The study will enroll 12 adults whose disease has not responded t…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis
Disease control Recruiting nowThis early study tests a new treatment called GC012F, made from a patient's own immune cells (CAR-T cells), for people with refractory generalized myasthenia gravis that hasn't responded to standard therapies. Six participants will receive a single infusion of these modified cell…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC